Caffeine (25mg) + Cetirizine (5mg) + Nimesulide (100mg) + Paracetamol (325mg) + Phenylephrine (5mg) (Medical Monograph)

Overview

A fixed-dose combination (FDC) analgesic, antipyretic, anti-inflammatory, and antihistaminic formulation designed for symptomatic relief of moderate to severe pain, fever, and allergic symptoms associated with conditions like the common cold, flu, sinusitis, and allergic rhinitis. It combines a non-narcotic analgesic (Paracetamol), a selective COX-2 inhibitor NSAID (Nimesulide), a second-generation antihistamine (Cetirizine), a nasal decongestant (Phenylephrine), and a central nervous system stimulant (Caffeine). The combination aims to provide synergistic relief from multiple symptoms. Note: The safety of Nimesulide is under scrutiny in many countries, and its use is restricted in India to a maximum of 15 days for acute conditions.

This combination exerts a multi-targeted effect. Paracetamol acts centrally on COX-3 and the serotonergic and cannabinoid pathways to reduce pain and fever. Nimesulide is a preferential COX-2 inhibitor, reducing prostaglandin synthesis at sites of inflammation, providing analgesic and anti-inflammatory effects. Cetirizine is a potent, selective peripheral H1-receptor antagonist, inhibiting histamine-mediated allergic symptoms. Phenylephrine is a selective alpha-1 adrenergic agonist causing vasoconstriction in nasal mucosa, reducing edema and congestion. Caffeine acts as an adjuvant analgesic, constricting cerebral blood vessels and potentially enhancing the absorption and efficacy of other analgesics.